Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23018464 | 1.00 | CYP19A1 (0.54) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL13220564 | 1.00 | CYP19A1 (0.54) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL4397862 | 1.00 | CYP19A1 (0.54) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL19609079 | 0.85 | CYP19A1 (0.42) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL2182130 | 0.83 | CYP19A1 (0.53) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL14606265 | 0.83 | CYP19A1 (0.49) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL28317353 | 0.83 | CYP19A1 (0.53) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL27581519 | 0.82 | CYP19A1 (0.50) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL19609078 | 0.82 | CYP19A1 (0.40) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 | |
| SCHEMBL4679066 | 0.81 | CYP19A1 (0.51) | CYP19A1EPHX1HTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346866-A1 | Functionalised Chromatography Medium Comprising Polymer Nanofibres and Process of Preparation Thereof | CYTIVA BIOPROCESS R&D AB (SE) | 2021-11-11 | — | — | US | disclosed |
| EP-3834926-A1 | FUNCTIONALIZED CHROMATOGRAPHY MEDIA | PURIDIFY LTD. (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-20210060527-A1 | Chromatography Media and Methods for Producing Them | CYTIVA BIOPROCESS R&D AB (SE) | 2021-03-04 | — | — | US | disclosed |
| EP-3484613-B1 | FUNCTIONALISED CHROMATOGRAPHY MEDIUM COMPRISING POLYMER NANOFIBRES AND PROCESS OF PREPARATION THEREOF | PURIDIFY LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-20190308169-A1 | Functionalised Chromatography Medium Comprising Polymer Nanofibres and Process of Preparation Thereof | CYTIVA BIOPROCESS R&D AB (SE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308169-A1 | Functionalised Chromatography Medium Comprising Polymer Nanofibres and Process of Preparation Thereof | C9, C1R, F3 | CYP19A1 1718/4885EPHX1 813/4885HTT 2501/4885 |
| US-20210346866-A1 | Functionalised Chromatography Medium Comprising Polymer Nanofibres and Process of Preparation Thereof | NEFM, SGMS1, FIBP | CYP19A1 4513/4885EPHX1 4027/4885HTT 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.